Table 5

Results of sensitivity analysis on the economic cost per IPTi dose delivered. Figures are United States cents, year 2005 (Tsh1205 = US$1)

Variables

Financial

Opportunity

Economic cost (Total)

Base case results

17.68

5.11

22.79

Low EPI coverage (71% nationwide)

23.41

6.76

30.18

Exclude sensitization at community level

16.92

4.00

20.9

Use of local brand SP Drug

8.44

4.85

13.29

Increase in salaries and per diem

20.97

5.74

26.71

Using generic drug, increasing salaries, excluding sensitization and lower EPI coverage

22.40

5.28

27.68

Manzi et al. BMC Health Services Research 2008 8:165   doi:10.1186/1472-6963-8-165